24/7 Market News Snapshot 24 Jul 2024 – Psyence Biomedical Ltd. Common Shares (NASDAQ: PBM)

July 24, 2024 3:30

Press Release

DENVER, Colo., 24 July, 2024 (247marketnews.com) – (Nasdaq:PBM) are discussed in this article.
Psyence Biomedical Ltd. (PBM) made headlines today with a remarkable 107.41% surge in stock price, opening at $0.389 and closing impressively at $0.8. This surge reflects a wave of investor confidence and strong market momentum, fueled by a trading volume of 8.3 million shares. The positive trend identified through technical analysis has investors eagerly awaiting further growth potential in the company’s common shares.

In a strategic move, Psyence Biomedical Ltd. is gearing up to begin a Phase IIb clinical trial involving nature-derived psilocybin. The company has recently exported the psilocybin to support the trial, which will evaluate its efficacy in treating Adjustment Disorder in patients with advanced cancer diagnoses in a Palliative Care setting. This pivotal research initiative underscores Psyence Biomedical Ltd.’s commitment to pioneering innovative treatment options in the healthcare landscape.

Expressing enthusiasm for this upcoming milestone, a company spokesperson highlighted the significance of exporting nature-derived psilocybin as a crucial step towards commencing the Phase IIb clinical trial. This trial marks a significant advancement in exploring the therapeutic potential of psilocybin in addressing the emotional challenges faced by individuals navigating advanced cancer diagnoses.

As Psyence Biomedical Ltd. progresses towards the trial initiation, the company remains dedicated to conducting comprehensive clinical research aimed at uncovering valuable insights and potential breakthroughs in mental health treatment. The anticipation is high as the company embarks on this transformative Phase IIb clinical trial, with a focus on evaluating the therapeutic benefits of nature-derived psilocybin for patients grappling with Adjustment Disorder in the Palliative Care context.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.